The two Medtronic Insulin Pump lawsuits allege failure of the devices to properly warn patients of an imbalance in their blood glucose levels, together with failure to administer the correct amount of insulin at critical periods to correct the imbalance. To a patient suffering from diabetes mellitus, such a correction performed accurately and properly timed is a key to survival.
In each Medtronic Insulin Pump lawsuit, there was a death. The mother of one of the victims and the executrix of the estate of the other victim are suing Medtronic for negligence. Allegations in each Medtronic lawsuit include lapses in good manufacturing practices and inadequate testing protocol.
And now there is a new wrinkle: the potential for device software to be hacked, further limiting the device’s integrity, or so it is alleged. According to the San Fernando Valley Business Journal (3/21/16), a former employee of IBM Corp., who served as a senior threat intelligence analyst while working for “Big Blue,” managed to hack into his own insulin pump and was able to manipulate levels of insulin delivered by the pump to his body at levels that could be potentially fatal.
The hacker, identified as Jay Radcliffe, is reported to have presented his findings at the Black Hat security conference in Las Vegas in 2011 without identifying the manufacturer, only to later reveal the manufacturer as Medtronic, and referencing four of its insulin pumps.
The report did not specifically break out what the four models were, and Radcliffe acknowledged that the probability of someone actually hacking into an insulin pump for sinister purposes is low, but he remains concerned so long as the capability is there.
And if the two plaintiffs in their respective Medtronic Insulin Pump lawsuits are already citing departures from good manufacturing practices and poor testing protocols, what related vulnerabilities might emerge at the software level?
The US Food and Drug Administration (FDA) has already taken Medtronic to task for violations in quality control protocols at Medtronic’s manufacturing facility located in Puerto Rico. Additionally, it was three years ago this month that Medtronic and the FDA issued a Class 1 Recall of Medtronic MiniMed Paradigm Insulin Infusion Sets over concerns that the pumps had the “potential for over or under delivery of insulin if insulin or other fluids contact the inside of Medtronic Paradigm Tubing Connectors,” effectively blocking vents integral for the priming function of the pump.
A similar recall in July of 2009 affected certain lots of the Medtronic MiniMed Paradigm insulin pumps that failed to properly vent air pressure integral to the accuracy of the pump. Over- or under-delivery of insulin could foster hypoglycemia or hyperglycemia, both of which can be fatal.
READ MORE MEDTRONIC INSULIN PUMP LEGAL NEWS
The Medtronic lawsuit is Hassan v. Medtronic MiniMed Inc. et al, Case No. 3:15-cv-2788, US District Court for the District of New Jersey.
READER COMMENTS
Forwhat Itsworth
on
With InFuse, the damage created by the product failure (in off-label use) brought about follow-up care including more of the InFuse product to correct at the bone level.
At the ongoing care level, Medtronic had two other product options for patients to deal with the failure of the first product.
In seems clear that Medtronic leadership dreams of replacing more and more of the human body with their products.
The result of the InFuse class action suit for 2000 people will total less than 20% of what Medtronic paid for falsified testing reports ($216M for 11 individuals and 2 universities), plus $85M in a shareholder suit, for being investigated by a senate panel.
Further, Medtronic met with Yale for a discussion on corporate accountability and corrective actions. I feel certain Yale participants expected disclosure of manufacturing and sales practice issues from which Yale would advise corrective actions aimed at eliminating current risks to life and longevity for current and potential patients.
Instead, it turned out to be how Medtronic could work side by side with Universities for better results in the future. Did all participants already expect the Medtronic solution of paying hundreds of millions of dollars for respected institutions to look the other way.
Is a business model where government approval (penalties), based on institutional research (grants), payola for doctors, and ultimately marginal/minimized payout for victims; a really sound business model - only if the first product will fail and additional Medtronic products are used for corrective action.
Short the stock, invest in their competitors if you must, but take Medtronic down and out.